We have located links that may give you full text access.
Impact of Human Immunodeficiency Virus Infection on Liver and Cardiovascular Outcomes in Veterans with Metabolic Dysfunction Associated Steatotic Liver Disease.
American Journal of Gastroenterology 2024 March 14
OBJECTIVE: Hepatic steatosis in highly prevalent in people living with human immunodeficiency virus (HIV). It remains unclear whether HIV in patients with metabolic dysfunction associated steatotic liver disease (MASLD) is associated with greater risks of liver disease progression and cardiovascular disease (CVD). We aim to evaluate the impact of HIV infection on risks of liver and CVD outcomes among U.S. Veterans with MASLD.
METHODS: Using national Veterans Administration data from 2010-2022, we created a propensity score matched cohort of MASLD patients with vs. without HIV. Primary outcomes were incidence of cirrhosis and hepatocellular carcinoma (HCC) among patients with vs. without HIV as well as MASLD-HIV patients on anti-retroviral therapy (ART) vs. not on ART. Secondary outcomes included incidence of major adverse cardiovascular events (MACE) and overall survival.
RESULTS: The propensity matched cohort included 920 MASLD patients with HIV and 920 MASLD patients without HIV and were similar in demographics and co-morbidities. Compared to MASLD patients without HIV, incidences of cirrhosis and HCC were similar among MASLD with HIV. Compared to MASLD patients without HIV, incidence of MACE was higher among MASLD patients with HIV (5.18 vs. 4.48 per 100 person-years, p=0.03). Overall 5-year survival was significantly lower among MASLD patients with HIV and even lower among those not on ART.
CONCLUSIONS: Among U.S. Veterans with MASLD, concurrent HIV infection, and particularly not being on ART, is associated with greater risks CVD and decreased overall survival. No differences in risks of cirrhosis or HCC were observed.
METHODS: Using national Veterans Administration data from 2010-2022, we created a propensity score matched cohort of MASLD patients with vs. without HIV. Primary outcomes were incidence of cirrhosis and hepatocellular carcinoma (HCC) among patients with vs. without HIV as well as MASLD-HIV patients on anti-retroviral therapy (ART) vs. not on ART. Secondary outcomes included incidence of major adverse cardiovascular events (MACE) and overall survival.
RESULTS: The propensity matched cohort included 920 MASLD patients with HIV and 920 MASLD patients without HIV and were similar in demographics and co-morbidities. Compared to MASLD patients without HIV, incidences of cirrhosis and HCC were similar among MASLD with HIV. Compared to MASLD patients without HIV, incidence of MACE was higher among MASLD patients with HIV (5.18 vs. 4.48 per 100 person-years, p=0.03). Overall 5-year survival was significantly lower among MASLD patients with HIV and even lower among those not on ART.
CONCLUSIONS: Among U.S. Veterans with MASLD, concurrent HIV infection, and particularly not being on ART, is associated with greater risks CVD and decreased overall survival. No differences in risks of cirrhosis or HCC were observed.
Full text links
Related Resources
Trending Papers
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology 2024 April 17
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Eosinophilic Esophagitis: Clinical Pearls for Primary Care Providers and Gastroenterologists.Mayo Clinic Proceedings 2024 April
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app